DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost

There are currently no licensed therapeutic treatment or preventive vaccines against Ebolavirus disease, and the 2013–2016 West African outbreak of Ebolavirus disease spread rapidly and resulted in almost 30,000 cases and more than 11,000 deaths. However, the devastating outbreak has spurred the dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Öhlund, Pontus, García-Arriaza, Juan, Zusinaite, Eva, Szurgot, Inga, Männik, Andres, Kraus, Annette, Ustav, Mart, Merits, Andres, Esteban, Mariano, Liljeström, Peter, Ljungberg, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102224/
https://www.ncbi.nlm.nih.gov/pubmed/30127450
http://dx.doi.org/10.1038/s41598-018-31003-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102224/
https://www.ncbi.nlm.nih.gov/pubmed/30127450
http://dx.doi.org/10.1038/s41598-018-31003-6

Ejemplares similares